Medical Grade Apixaban Powder Anticoagulants Apixaban

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Apixaban
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Apixaban
• CAS No: 503612-47-3
• Molecular Formula: C25h25n5o4
• Molecular Weight: 459.497 G/Mol
• Appearance: White to off-White Powder
• Identification: Retention Time Matches Standard
• Related Substances: Individual ≤ 0.5%, Total ≤ 1.5%
• Residual Solvents: Meets Ich Q3c Limits
• Water Content: ≤ 1.0% W/W
• Heavy Metals: ≤ 20 Ppm
• Sulfated Ash: ≤ 0.1% W/W
• Column: C18, 250 mm × 4.6 mm, 5 µm
• Flow Rate: 1.0 Ml/Min
• Detection Wavelength: 220 Nm
• Column Temperature: 30°c
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS
• Origin: Xian
• Production Capacity: 2000 Kg/Month

Product Description

Medical Grade Apixaban Powder Anticoagulants Apixaban

Product Description

Product Details

Product Name	Apixaban
Apperance	White to off-white powder
CAS	503612-47-3
MF	C25H25N5O4
MW	459.497 g/mol

Apixaban is a highly selective and reversible factor Xa inhibitor, with the chemical name 4,5,6,7-tetrahydro-1- (4-methoxyphenyl) -7-oxo-6- [4- (2-oxo-1-piperidinyl) phenyl] -1H-pyrazolo [3,4-c] pyridine-3-carboxamide, molecular formula C25H25N5O4, and molecular weight 459.5023. This compound is a white to white crystalline substance with a purity of ≥ 99.5% (HPLC). It is mainly used for antithrombotic therapy and belongs to a new type of oral anticoagulant drug16. Its advantages include efficient inhibition of thrombin production, lower risk of bleeding, and fewer drug interactions, making it suitable for preventing stroke and systemic complications in patients with non valvular atrial fibrillation.

Application&Function

Apixaban specifically inhibits coagulation factor Xa to block the coagulation cascade and reduce thrombus formation. Clinical studies have shown that it can significantly reduce the risk of venous thromboembolism (VTE), especially in patients after hip/knee replacement surgery, with better efficacy than traditional anticoagulants such as enoxaparin, and does not increase the probability of bleeding. In addition, Apixaban has demonstrated stroke prevention advantages in patients with atrial fibrillation and has stable pharmacokinetic properties (oral bioavailability of 58% -59%, half-life of approximately 5.8 hours). Currently approved for relevant indications in multiple countries worldwide.

Specification

ABOUT US